云南白药(000538.SZ)：公司INR101诊断核药项目，已启动Ⅲ期临床试验

Core Viewpoint - Yunnan Baiyao (000538.SZ) is making progress in its nuclear medicine research, specifically in the INR101 and INR102 projects, with ongoing clinical trials [1] Group 1: INR101 Diagnostic Nuclear Medicine Project - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials [1] - A total of 32 research centers have been established for the project, with 22 centers currently active [1] - 60 subjects have been enrolled in the clinical trial [1] Group 2: INR102 Therapeutic Nuclear Medicine Project - The INR102 therapeutic nuclear medicine project has received a clinical trial notification [1] - Phase I clinical trial research centers have been activated [1] - The investigator-initiated clinical trial (Phase II T) has successfully enrolled and administered treatment to 12 patients [1]